RSV Surges Past Flu: Australia's Top Winter Virus

Respiratory syncytial virus (RSV) has officially become Australia's most prevalent respiratory virus this winter, marking a significant shift as it now exceeds influenza. This development is a first since national reporting for the disease commenced in 2021.

Nationwide, over 83,000 RSV cases have been documented this year. The Immunisation Foundation of Australia highlights that nearly 900 new infections are reported daily during the winter period.

Despite the escalating case numbers, vaccine uptake for RSV remains notably lower than for influenza. Over 1.76 million eligible older Australians have received their flu vaccine, in stark contrast to the 722,530 who have opted for the free RSV vaccine, indicating over one million remain unprotected.

This gap is partly attributed to the free RSV vaccine only recently becoming available to older Australians two months ago. Previously, the vaccine cost approximately $300 per dose, presenting a significant financial barrier for many. Health experts are urging eligible individuals, particularly those aged 75 and over, and Aboriginal and Torres Strait Islander people aged 60 and over, to get vaccinated.

RSV can lead to severe illness, hospitalisation, and even death, especially in vulnerable populations. Symptoms often mimic a common cold but can escalate to complications like pneumonia. Vaccination is crucial in preventing severe outcomes and reducing hospitalisations, as demonstrated by a aged care provider in Perth which experienced limited outbreaks after facilitating resident vaccinations.